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Epithelial cell adhesion molecule EpCAM is a transmembrane glycoprotein that is frequently overexpressed in a variety of carcinomas.
This pan-carcinoma antigen has served as the target for a plethora of immunotherapies. Innovative therapeutic approaches include
the use of trifunctional antibodies (trAbs) that recruit and activate different types of immune effector cells at the tumour site. The
trAb catumaxomab has dual specificity for EpCAM and CD3. In patients with malignant ascites, catumaxomab significantly increased
the paracentesis-free interval, corroborating the high efficacy of this therapeutic antibody. Here, we characterised the monoclonal
antibody (mAb) HO-3, that is, the EpCAM-binding arm of catumaxomab. Peptide mapping indicated that HO-3 recognises a
discontinuous epitope, having three binding sites in the extracellular region of EpCAM. Studies with glycosylation-deficient mutants
showed that mAb HO-3 recognised EpCAM independently of its glycosylation status. High-affinity binding was not only detected for
mAb HO-3, but also for the monovalent EpCAM-binding arm of catumaxomab with an excellent KD of 5.6 10
 10M. Furthermore,
trAb catumaxomab was at least a 1000-fold more effective in eliciting the eradication of tumour cells by effector peripheral blood
mononuclear cells compared with mAb HO-3. These findings suggest the great therapeutic potential of trAbs and clearly speak in
favour of EpCAM-directed cancer immunotherapies.
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EpCAM (CD326) is a type I transmembrane glycoprotein that
acts as a Ca
2þ independent homophilic cell adhesion molecule
(Litvinov et al, 1994). The 39–42kDa protein is composed of a
large extracellular domain with two EGF-like repeats, a single
transmembrane region, and a short cytoplasmic tail of 26 amino
acids (Balzar et al, 1999). The high frequency of its overexpression
in a multitude of human carcinomas qualifies EpCAM as a target of
interest for immunotherapy. High-level EpCAM expression was
demonstrated in major malignancies such as colon, stomach, and
prostate cancers and in adenocarcinoma of the lung (Went et al,
2006). Besides being a target antigen, EpCAM is a prognostic
marker in breast, ovarian, and gallbladder cancers where its
overexpression correlates with poor prognosis (Gastl et al, 2000;
Spizzo et al, 2002, 2006; Varga et al, 2004). The therapeutic
potential for the inhibition of EpCAM was illustrated by a
knockdown phenotype of EpCAM in carcinoma cells. Treatment
of head neck, and breast cancer cells with EpCAM-specific
antisense or siRNAs resulted in the reduction or even abrogation
of cell proliferation, migration, and invasive capacity (Munz et al,
2004; Osta et al, 2004).
Moreover, EpCAM supports active escape from immune surveil-
lance. Ectopic expression of EpCAM in dendritic cells blocks their
ability to present MHC class II-restricted antigens (Gutzmer et al,
2004). All these features have encouraged the development of various
EpCAM-directed anti-cancer therapies. Trifunctional antibodies
(trAbs) with a dual specificity for EpCAM expressed on tumour
cells and CD3 expressed on T cells represent an innovative
immunotherapeutic approach to fight cancer. TrAbs induce a tri-
cell complex of tumour cells, T cells, and accessory immune cells due
to their unique Fc-composition of mouse IgG2a and rat IgG2b.
Thereby, crosstalk between different types of redirected immune
effector cells is initialised, that results in efficient killing of the
tumour cells (Zeidler et al, 1999, 2000; Riesenberg et al, 2001).
Encouraging first clinical results confirm those observed in in vitro
anti-tumour potency studies. Positive indication of clinical benefit in
the treatment of metastatic breast cancer came from a phase I dose
escalation trial using a HER-2-specific trAb (Kiewe et al, 2006).
Moreover, the feasibility of combining trAbs with high-dose
chemotherapy for metastatic breast cancer treatment was shown in
a pilot study (Stemmler et al, 2005). Finally, trAbs were safely applied
and demonstrated convincing efficacy in patients suffering from
malignant ascites (Heiss et al, 2005).
Here, we report on the characterisation of the new monoclonal
antibody (mAb) HO-3 that constitutes the EpCAM-binding arm of
the corresponding trAb catumaxomab (removab
s). A detailed
analysis of the binding features and anti-tumour efficacy of HO-3
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sin comparison with catumaxomab is presented. Furthermore, we
discuss the impact of the binding kinetics with respect to
immunotherapy of EpCAM-positive tumours by conventional
monoclonal vs trifunctional antibodies.
MATERIALS AND METHODS
Generation of HO-3 hybridoma
Balb/c mice were immunised by intraperitoneal injection of the
EpCAM-positive human colon carcinoma cell line HCT-8 (ATCC
No. CCL-224). One week after a booster immunisation, the mice
were killed and spleen cell preparations were fused with the mouse
myeloma cell line P3X63Ag8.653 (ATCC No. CRL 1580). Super-
natants of single growing clones were screened for competitive
binding with anti-EpCAM mAb C215 to HCT-8 cells by flow
cytometry. The isolated hybridoma clone HO-3 was further
stabilised by several rounds of subcloning. It produces mouse
antibodies of the subtype IgG2a.
Antibodies and EpCAM antigen
The EpCAM-specific antibodies C215 (Bjork et al, 1993), VU-1D9
(Balzar et al, 1999), HO-3 and the anti-mouse Thy-1.2. isotype
control MmT1 (Kremmer et al, 1989) were all produced by
hybridoma technology and protein G (GE Healthcare, Uppsala,
Sweden) affinity purification at TRION Research. Catumaxomab
(removab
s), the trAb variant of HO-3 with a dual specificity for
EpCAM and CD3 and the trifunctional control antibody Bi20 (anti-
CD20 anti-CD3) were manufactured using the quadroma tech-
nology (Lindhofer et al, 1995) at TRION Pharma (Munich,
Germany) under GMP conditions.
The extracellular domain (ECD) of the human EpCAM protein
was heterologously expressed in the yeast strain pichia pastoris at
GenYouIn Biotech (Reutlingen, Germany). C-terminal addition of
a His6 tag allowed metal-affinity purification of the protein via Ni
NTA agarose (Qiagen, Hilden, Germany).
Establishing EpCAM glycosylation mutants
Asparagine residues within the NGT/S N-glycosylation consensus
sequence at amino-acid positions 74, 111, and 198 were changed to
alanines by PCR-based site directed mutagenesis. A triple knock-
out mutant was generated by sequential single mutations using the
primers shown in Table 1. PCR amplification products were
subcloned into the PCR cloning vector pDRIVE (Qiagen) before
transfer into the eukaryotic expression vector pcDNA3.1-hygro
þ
(Invitrogen, Heidelberg, Germany) for transient transfection of
HEK293 cells. Empty vector was used as a negative control for
transfection and subsequent detection by flow cytometry. The
glycosylation status of the proteins was assessed with the
glycostain kit (Molecular Probes, Go ¨ttingen, Germany) according
to the manufacturer’s instructions.
Construction of an EGF-like domain I EpCAM deletion
mutant
Deletion of the EGF-like domain I (amino acids 27–59) was
performed by overlapping PCR mutagenesis with the primers
listed in Table 1. PCR fragments were subcloned into the pDRIVE
vector and subsequently transferred into pcDNA3.1-hygro
þ using
the Nhe1 and Xba1 restriction enzyme sites. Transiently trans-
fected HEK293 cells, including a positive control plasmid
expressing wild-type EpCAM, were then analysed by flow
cytometry and immunoblot. Similar transfection efficiency for
each sample was assessed with the GFP expression plasmid
pEGFP-C1 (BD Clontech, Heidelberg, Germany).
Fluorescence-activated cell sorting analysis
Competitive binding to native EpCAM and binding to the above
mentioned EpCAM glycosylation mutants was performed by flow
cytometry using a fluorescence-activated cell sorting (FACS)Cali-
bur device and the Cellquest pro software (Becton Dickinson,
Heidelberg, Germany). Competitive binding assays were per-
formed by preincubation of 2 10
5 HCT-8 target cells with
EpCAM specific mAbs C215 or VU-1D9 at the indicated amounts
for 10min. After a washing step with FACS buffer (PBS
supplemented with 1% FCS and 0.1% sodium azide) cells were
incubated with 2.5mgml
 1 FITC-labelled HO-3mAb for 30min,
washed, and analysed by comparing the mean fluorescence
intensity (MFI) relative to a mouse IgG2a, kappa isotype control
(BD Pharmingen).
Analysis of HO-3 or C215 binding to native EpCAM mutants was
done using HEK293 cells stably or transiently transfected with the
Table 1 Primers used for PCR-based site directed mutagenesis of epithelial cell adhesion molecule (EpCAM)
Primers used for amplification of PCR products after mutagenesis
External primer 1:5 0-GGCACCAAAATCAACGGGAC-30
External primer 2:5 0-AGGGTCAAGGAAGGCACGG-30
Primers used for generation of glycosylation mutants
N74A-fw int. primer (internal primer 1)
50-TGGTGATGAAGGCAGAAATGGCAGGCTCAAAACTTGGGAGAAG-30
N74A-bw int. primer (internal primer 3)
50-CTTCTCCCAAGTTTTGAGCCTGCCATTTCTGCCTTCATCACCA-30
N111A-fw int. primer (internal primer 2)
50-AGGCCAAGCAGTGCGCGGGCACCTCCACGTG-30
N111A-bw int. primer (internal primer 4)
50-CACGTGGAGGTGCCCGCGCACTGCTTGGCCT-30
N198-fw int. primer
50-AATGTTATCACTATTGATCTGGTTCAAGCCTCTTTCTCAAAAAACTCAGAATGATGTG-30
N198-bw int. primer
50-CACATCATTCTGAGTTTTTTGAGAAGAGGCTTGAACCAGATCAATAGTGATAACATT-30
Primers used for generation of EGF I deletion mutant
Internal primer 1
50-CACCAAACATTTGGCAGCCAGCTTTGAACATTCTTCCTGAGCTGCGGCAAA-30
Internal primer 2
50-TTTGCCGCAGCTCAGGAAGAATGTTCAAAGCTGGCTGCCAAATGTTTGGTG-30
Abbreviations: A¼alanine; bw¼reverse; fwd¼forward; int¼internal; N¼asparagines.
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sabove mentioned expression vectors. Therefore, 14–20mgml
 1
primary antibodies were each incubated with 2 10
5 cells for
30min. After washing three times, the PE or FITC-labelled rat-anti-
mouse IgG detection antibody (Dianova, Hamburg, Germany) was
added. Cells were washed again, and the MFI of the stained cells
was determined.
Epitope mapping
The EpCAM epitope recognised by the HO-3 antibody was defined
by screening a peptide library covering amino acids 7–268. The
22-residue N-acetylated peptides with a 16 amino-acid overlap
were directly synthesised on a cellulose membrane by spot
synthesis as described by Reineke et al (1999). After incubation
with HRP-labelled HO-3 antibody, the chemiluminescence signal
intensity was quantified with an imaging system as BLU
(Boehringer light units). The epitope mapping studies were carried
out at Jerini Peptide Technologies (Berlin, Germany).
Affinity measurement
The affinity of HO-3 and catumaxomab for the EpCAM protein
was determined via surface plasmon resonance (SPR) using a
Biacore 3000 device (Biacore AB, Uppsala, Sweden). The ECD of
EpCAM was covalently coupled to a CM-5 sensor chip at low
density (215 response units of EpCAM). Binding kinetics were
performed with twofold serial dilutions of antibody at concentra-
tions of 500–0.08nM in running buffer (PBS, pH 7.4, 0.005% (v/v),
polysorbate 20 – filtered and degassed) at 251C and a flow rate of
25mlmin
 1. The regeneration procedure consisted of three
injections of 10ml 2.5M guanidinium hydrochloride followed by
flushing of the sensor chip with running buffer for 5min.
Statistical and data processing were performed with BIA evaluation
software 4.0.1 and GraphPad Prism 4.02 (GraphPad Software Inc.,
San Diego, CA, USA). All SPR experiments were carried out at
Biaffin GmbH & Co KG (Kassel, Germany).
Tetrazolium hydroxide cytotoxicity assay
Peripheral blood mononuclear cells (PBMC) (1 10
5 cells) from
healthy donors were isolated by ficoll density centrifugation and
subsequently mixed with 1 10
4 HCT-8 tumour cells in the
presence of the indicated amounts of antibodies in 96-well flat
bottomed plates (final volume 200ml RPMI-1640 medium contain-
ing 10% FCS, 1mM sodium pyruvate, 2mML -glutamine, and
1 non-essential amino acids). After 3 days of co-cultivation at
371C and 5% CO2, soluble PBMC were washed twice with PBS
without Ca
2þ Mg
2þ (PAN Biotech, Aidenbach, Germany). Then,
adherent tumour cells were stained with tetrazolium hydroxide
(XTT) cell proliferation kit II (Roche Diagnostics GmbH,
Mannheim, Germany) until the OD650nm-490nm of the tumour cell
control samples reached a value of about 1.5. Plates were measured
with a VersaMax plate reader (Molecular Devices, CA, USA) with
background values with medium alone subtracted. Killing
efficiency of HO-3 and catumaxomab was assessed in a total of
four independent experiments with fourfold determinations of
each sample. Tumour cell killing (%) was calculated according
to the formula: (ODtumour cells ODtumour cellsþPBMCþantibody)/
(ODtumour cells–ODPBMC) 100%.
RESULTS
C215, but not VU-1D9, competes with HO-3 for binding to
EpCAM
To confirm the specificity of the mAb HO-3 for EpCAM, we
performed binding assays in the presence of the mAbs C215 and
VU-1D9. Both C215 and VU-1D9 bind with high-affinity to the
EGF-like domain I of EpCAM (Balzar et al, 1999). As depicted in
Figure 1, C215 clearly inhibited the binding of HO-3 to EpCAM-
positive HCT-8 cells in a dose-dependent manner, whereas
VU-1D9 did not. A 10-fold excess of preadded mAb C215 entirely
blocked HO-3 binding to EpCAM-positive cells suggesting that
both antibodies recognise similar epitopes.
HO-3 binds within the EGF I repeat of EpCAM
The C215 antibody binds within the EGF-like domain I of EpCAM
(Bjork et al, 1993). Given the fact that C215, but not VU-1D9,
competed for the binding of HO-3 to EpCAM, we anticipated
similar binding sites for C215 and HO-3. To test our assumption,
flow cytometry assays were conducted to assess the binding
activity of HO-3 to an EpCAM deletion mutant lacking the EGF-
like domain I (EGFmut; amino acids 27–59). Indeed, the reactivity
of HO-3 towards the deletion mutant was strongly impaired when
compared to the recognition of an EpCAM wild-type control
(Figure 2A). A similar loss of binding to the EGF-like domain
mutant was observed for the mAb C215, which was used as a
control. However, in both cases residual binding activity could be
detected. A comparably strong, though not complete, loss of
binding activity for mAbs HO-3 and C215 was observed when
EpCAM-EGFmut was detected in its denatured form by immuno-
blotting (Figure 2B). These results define the binding specificity of
HO-3 and C215 within EpCAM’s EGF-like domain I, but point
towards additional binding sites beyond this particular protein
stretch.
HO-3 recognises a discontinuous epitope, having three
binding sites in EpCAM
Next, the binding specificity of HO-3 was fine-mapped by
screening a peptide library covering the complete ECD of EpCAM
(amino acids 7–268). We analysed 22-residue peptides, with a
16-amino-acid overlap, to achieve high-resolution mapping. The
synthetic peptide library included the amino acid sequence
ranging from residues 31 to 52 of wild-type EpCAM that was
most strongly targeted by mAb C215 (Bjork et al, 1993). Screening
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Figure 1 C215, but not VU-1D9, competes with mAb HO-3 for binding
to wild-type EpCAM. Preincubation of HCT-8 tumour cells with mAb
C215 blocked HO-3 binding by more than 50% relative to the positive
control (B) with no competitor when the antibodies were added at equal
concentrations (2.5mgml
 1). A 10-fold excess of mAb C215 (25mgml
 1)
resulted in almost complete binding inhibition, which was down to the level
of the isotype control (A; IgG2a, kappa). Preincubation of cells with VU-
1D9 did not significantly influence HO-3 binding. Triangles indicate
escalating amounts of competitor antibody with HO-3 concentration kept
constant at 2.5mgml
 1. Each sample was measured three times; error bars
indicate s.d. The experiment was repeated with similar results.
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sthe peptide library with the C215 control antibody confirmed the
recognition of two peptides at amino acid positions 31–52 and
103–124 (Table 2). Interestingly, mAb HO-3 recognised a
conformational epitope, indicating the presence of three EpCAM
binding sites. A comparison of the amino acid sequences
recognised by C215 and HO-3 revealed an overlap in the epitope
within the EGF-like domain I. This common binding region readily
explains the competitive reactivity of both investigated antibodies.
However, an additional major HO-3 binding site was localised
within the EGF-like domain II between amino acids 67 and 88. A
third binding site situated more C-terminally (103–124) could also
be identified. Notably, there was no cross-reaction with murine
EpCAM (data not shown).
HO-3 and the corresponding trAb catumaxomab bind with
high affinity to EpCAM
Binding of HO-3 to EpCAM-positive target cells, as measured by
flow cytometry, pointed toward a high-affinity antibody (data not
shown). Surface plasmon resonance was applied to determine the
exact binding constants for HO-3. For this purpose, the
recombinant ECD of native EpCAM was expressed in yeast, and
the antibody–antigen interaction was investigated with Biacore
technology. Both HO-3 and the corresponding trAb catumaxomab
revealed high affinities, with low dissociation constants of
5.5 10
 10 and 5.6 10
 10M, respectively (Table 3). Owing to
the low EpCAM antigen density covalently linked to the sensor
chip, these values mainly reflect monovalent binding. After
increasing EpCAM density avidity effects of bivalent HO-3
binding, indicated by reduced-off rates, were observed (data not
shown).
Recognition of EpCAM by HO-3 is independent of
EpCAM’s glycosylation status
The amino acid sequence of EpCAM comprises three putative
N-glycosylation sites (NGT/S) (Chong and Speicher, 2001).
Differential usage of these N-glycosylation sequences results in
the generation of EpCAM variants of different sizes ranging from
37 to 42kDa. Notably, a hyperglycosylation pattern was observed
in head and neck carcinoma when compared with healthy EpCAM-
positive epithelium (Pauli et al, 2003).
EpCAM was strongly glycosylated in 77% of cases of head and
neck carcinomas studied (n¼44). When comparing pairs of
carcinomas and EpCAM-positive thyroid tissue from the same
patients (n¼26), a significant hyperglycosylation of EpCAM in
tumours was observed in 80.7% of specimen. Hence, we wondered
whether protein glycosylation might eventually play a role in
antibody recognition, as this would have serious repercussions on
therapeutic application.
Point mutations were sequentially inserted into the extracellular
domain of wild-type EpCAM to exchange asparagine residues in
each N-glycosylation consensus site to an alanine (N-A)t o
generate a triple mutant (N74/111/198A). This EpCAM triple
mutant lacking all consensus asparagine residues (N74A, N111A,
N198A) was unglycosylated, as shown on glycostaining
(Figure 3A). Thereafter, independent bulk cultures of EpCAMwt
and N74/111/198A stable HEK293 transfectant were stained with
mAb HO-3 or C215 and measured in a flow cytometer. EpCAM was
detected by both the HO-3 and C215 antibodies and independently
of the glycosylation status, that is EpCAMwt and N74/111/198A
were equally well bound (Figure 3B). Hence, binding of HO-3 to
EpCAM is not affected by the glycosylation status of the protein.
Catumaxomab, but not HO-3, efficiently mediates tumour
cell killing in vitro
The capacity of HO-3 or the therapeutic trAb catumaxomab to
induce the killing of EpCAM-positive tumour cells by immune
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Figure 2 HO-3 binds within EGF-like domain I of EpCAM. (A) HEK293
were transiently transfected with wild-type EpCAM or the EpCAM EGF-I
mutant and stained with HO-3 (grey curves; upper panels) or C215 (grey
curves; lower panels) in combination with a PE-conjugated secondary
antibody. As a control, primary Ab was omitted (black line). (B)
Transfections were performed as in (A), proteins were separated by
10% SDS–PAGE, and EpCAM was visualised with the mAb HO-3. For a
control, levels of actin were assessed on the same membrane. Shown are
the representative results from three independent experiments.
Table 2 Identification of EpCAM peptides recognised by HO-3 and
C215.
AA
position Peptide sequence
Signal intensity
(BLU) mAb
49–70 TSVGAQNTVICSKLAAKCLVMK 6829 HO-3
67–88 LVMKAEMNGSKLGRRAKPEGAL 18813 HO-3
175–196 QLDPKFITSILYENNVITIDLV 3543 HO-3
31–52 NYKLAVNCFVNNNRQCQCTSVG 16703 C215
103–124 GLFKAKQCNGTSTCWCVNTAGV 12006 C215
Screening a peptide library covering the complete ECD of EpCAM showed that the
listed peptides had the strongest interaction with the indicated antibody. Signals
ranging from 30 to 800 Boehringer Units (BLU) were considered to be non-specific
(background).
Table 3 Determination of kinetic constants for antibody-EpCAM
interactions.
Antibody kass (M
 1s
 1)k diss (s
 1)K D (M)
HO-3 5.471.6 10
4 2.770.8 10
 5 5.5 10
 1070.19
Catumaxomab 6.171.5 10
4 3.370.3 10
 5 5.6 10
 1070.12
Interaction between the ECD of native EpCAM and mAb was measured by surface
plasmon resonance. Both the parental mAb HO-3 and the trAb variant
catumaxomab displayed high-affinity binding with slow off rates.
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seffector cells was compared in vitro. The cytotoxic potential of
PBMC was assessed by XTT staining after co-cultivation of PBMC
and EpCAM-positive tumour targets for 3 days. Significant tumour
cell eradication was observed after addition of trAb catumaxomab
at low concentration of 0.1ngml
 1. Tumour cells were quantita-
tively killed at concentrations greater than 10 ngml
 1 (Figure 4).
EpCAM-independent killing induced by CD20-specific trifunc-
tional control antibody Bi20 was approximately 40%. Similar
results were obtained using PBMC from different donors (n¼4).
In sharp contrast, HO-3 mediated a weak killing efficiency only at
a favourable effector to target ratio of 50:1 and at concentrations
as high as 100ngml
 1. As expected, HO-3-mediated killing was
specific since mouse IgG2a isotype control antibody did not
display any anti-tumoral activity. In summary, catumaxomab
and HO-3 exhibit a strong potency difference with regard to
their ability to induce the killing of EpCAM-positive cancer cells
in vitro.
DISCUSSION
Soon after its discovery, the high frequency of EpCAM over-
expression in many epithelial tumours suggested it as an attractive
target for antibody-based therapies (Herlyn et al, 1979; Gottlinger
et al, 1986a; Riethmuller et al, 1994). Since then, there have been a
plethora of therapeutic approaches guided by the idea of targeting
tumour cells via EpCAM. These strategies include the use of
murine and humanised monoclonal antibodies, retroviral con-
structs, vaccination protocols, as well as bispecific and trifunc-
tional antibodies (Balzar et al, 1999; Armstrong and Eck, 2003;
Kufer et al, 2004; Baeuerle and Gires, 2007).
Here, we characterise the new mAb HO-3 that constitutes the
EpCAM-binding arm of the corresponding therapeutic trAb
catumaxomab. The binding features of this mouse IgG2a antibody
are described in detail. Studies with EpCAM deletion mutants and
binding assays in the presence of the competing mAb C215 pointed
toward a recognition site within the EGF-like domain I in the
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Figure 3 HO-3 and C215 recognise EpCAM independently of the glycosylation status. (A) HEK293 cells were stably transfected with an expression
vector for wild-type EpCAM and a triple mutant lacking all glycosylation sites (EpCAMmut). Equal amounts of cell lysates of each cell lines were separated by
10% SDS–PAGE and subjected to glycostaining. Staining was assessed with the FLA 5000 scanning device (Fuji). M represents an internal marker provided
by the manufacturers. (B) HEK293 cells stably expressing wild-type EpCAM, a triple mutant lacking all N-glycosylation consensus sites (N74/111/198A;
EpCAMmut), or the empty vector for a control were stained with HO-3 (grey curves; upper panels) or C215 (grey curves; lower panels) in combination with
a FITC-conjugated secondary antibody. As a control, primary antibody was omitted (black line). All data are representative results from three independent
experiments.
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Figure 4 TrAb catumaxomab is 1000-fold more potent than HO-3 in
eliciting PBMC-mediated killing of EpCAM-positive carcinoma cells.
Comparison of trAb and mAb mediated cytotoxicity against EpCAM-
positive tumour cells in vitro. HCT-8 tumour cells and PBMCs were
co-cultured at ratios of 10:1 in the presence of trAbs catumaxomab (anti-
EpCAM anti-CD3), Bi20 (anti-CD20 anti-CD3) or mAb HO-3 at the
indicated concentrations. Additional approaches with high effector ratios of
50:1 were performed for H0-3 and mouse IgG2a isotype control MmT1
(anti-mouse Thy-1.2). After 3 days, tumour cell killing was measured by
XTT staining. Alloreactivity of PBMC without antibody was not significant
(0–2%). Data points display mean values of four determinations with s.d.
Data are representative results from four independent experiments using
PBMCs from different donors.
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sextracellular domain of EpCAM. This was confirmed by fine-
mapping the antigenic epitope through the screening of an
overlapping peptide library which revealed a discontinuous
epitope with two major binding sites within the EGF I and the
EGF II domains, respectively. A third minor binding site located
C-terminally to EGF II was also identified. Thus, HO-3, just like
the great majority of EpCAM-specific antibodies, targets EpCAM
mainly within the EGF like domains, which represent the most
immunogenic components of this protein (Balzar et al, 1999).
Driven by the knowledge of differential glycosylation of EpCAM in
normal vs carcinoma tissue (Pauli et al, 2003), we assessed the
dependence of HO-3 binding on the glycosylation status of the
molecule. A potential impact of post-translational modification of
EpCAM on the binding of therapeutic antibodies available so far
remained entirely unexplored. Nevertheless, this may be of major
importance as suggested by the tumour antigen MUC-1 whose
hypoglycosylated variant expressed in tumour tissue is differen-
tially recognised by mucin-specific antibodies (Grinstead et al,
2002; Karsten et al, 2005; Li and Cozzi, 2007). However, HO-3
binding to EpCAM was entirely independent of the presence of
glycosyl residues on the target protein. Of note, the glycosylation
grade of EpCAM derived from head and neck squamous cell
carcinomas varied, and it is as yet unclear whether weakly or non-
glycosylated EpCAM variants may appear on other tumours.
Taking this into account, mAbs such as HO-3 that are insensitive
to the glycosylation status of EpCAM have an expanded potency to
target a great variety of EpCAM-positive tumours.
Certainly, the most interesting aspect of new antibodies against
EpCAM is their therapeutic value. Upto now, edrecolomab
(Panorex
s) is one of the best characterised EpCAM-specific
therapeutic antibodies (Gottlinger et al, 1986b; Goodwin et al,
1987). However, the clinical benefit of this mouse IgG2a mAb is
limited. Having first shown impressive reduction in mortality in
Duke’s C colorectal cancer patients compared with the control arm
consisting of surgery alone, edrecolomab proved to be less
effective than chemotherapy in a proximate phase III study
(Riethmuller et al, 1994; Punt et al, 2002). The low affinity of the
antibody is one critically discussed aspect. Improved treatment
results with the strongly binding mAb 323/A3 in a mouse xenograft
tumour model speak in favour of the clinical development of high-
affinity anti-EpCAM therapeutic antibodies (Velders et al, 1995).
However, the maximum tolerated dose of the high-affinity
EpCAM-targeting mAb ING-1, as determined in a dose escalation
study, turned out to be low, with only 0.1mgkg
 1 i.v. Additionally,
severe toxicity in the form of acute pancreatitis occurred at higher
concentrations (de Bono et al, 2004). Keeping the affinity low but
improving ADCC effector function by chimaerisation or genera-
tion of fully human IgG1 antibodies may be a more promising
method. With adecatumumab (MT201), such a novel human IgG1
anti-EpCAM antibody is presently in clinical development
(Naundorf et al, 2002). However, common mAb effector functions
such as ADCC and CDC may not be strong enough in terms of
cancer therapy. High antibody dosages and continued adminis-
tration are required to compensate for the endogenous serum IgG
that competes for binding to Fcg receptors on immune effector
cells, and complement inhibitors that are expressed on tumour
cells (Gorter and Meri, 1999; Preithner et al, 2006).
TrAbs represent a novel and promising alternative to improve
anti-cancer efficacy. Owing to the simultaneous recruitment
and activation of T cells and accessory immune cells, a variety of
effector functions, such as ADCC, phagocytosis, and T-cell
mediated cytotoxicity, are induced in a combinatorial fashion
(Zeidler et al, 1999, 2000; Riesenberg et al, 2001). This may lead to
a 1000-fold increase in anti-tumour potency as was demonstrated
in the present study. The trAb catumaxomab (removab
s), which is
based on the mAb HO-3 and displays specificities for EpCAM and
CD3, is far more potent in inducing tumour cell killing by PBMC
than is HO-3 alone. Besides the trAb-mediated concerted attack by
different types of effector cells, the high affinity of the anti-EpCAM
binding arm may contribute to its effectiveness as an anti-tumour
agent. Not only for HO-3, but also for monovalently binding
catumaxomab, we measured a remarkably low dissociation
constant of 5.6 10
 10M. As EpCAM is not tumour-specific, but
rather is tumour-associated and also expressed on normal
epithelial tissue (Balzar et al, 1999), high affinity conventional
mAbs may be disadvantageous, with therapeutic concentrations
that cause severe adverse events. This is different with trAbs, which
are administered in the clinic at very low dosages in the microgram
range. However, to guarantee effective and stable opsonisation of
tumour cells, a very high-affinity and a slow-off rate of the
therapeutic antibody is required, especially when administered at
non-saturating concentrations. Hence, we propose that the high-
affinity and the assessed off rate of only 3.370.3 10
 5 s
 1 of the
anti-EpCAM targeting arm is one of the crucial features of
catumaxomab.
The therapeutic effectiveness of this novel trAb has not only
been demonstrated in vitro and in different in vivo tumour models
(Lindhofer et al, 1996; Ruf and Lindhofer, 2001; Schmitt et al,
2004). Catumaxomab’s clinical benefit was recently verified when it
was used to treat patients suffering from malignant ascites (Heiss
et al, 2005). In this prospective study, catumaxomab was applied
intraperitoneally, was well tolerated, and effectively diminished the
local tumour cell burden and ascites fluid accumulation.
Biodistribution studies in EpCAM transgenic mice suggested
preferential access of EpCAM-specific mAbs to tumour cells in
spite of a background expression of EpCAM on healthy tissue
(McLaughlin et al, 2001). This demonstrates the suitability of using
EpCAM for antibody-based cancer therapy, in principle. In
conclusion, the application of high-affinity and effective trAbs
administered locally at very low concentrations may re-open the
therapeutic window for immunotherapy of EpCAM expressing
tumours.
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